Investor Presentation

Investor Presentation - Q1FY27 - Revenue from operations 18,003 Mn +20% y-y; PAT 3,170 Mn +47% y-y - CDMO revenue grew 20% y-y supported by recent product launches; B2B revenue up 19% y-y on volume growth - Launched 4 new molecules in the USA including Multi-Vitamin and Leucovorin calcium - Filed 3 ANDAs and received 7 approvals in Q1FY27; total 389 filings with 342 approvals - Strategic partnerships include CDMO deal with global pharma (USD 90-100 mn potential) and collaboration with Neuland Laboratories - R&D expenses at 4% of revenue focused on complex product development - US market contributed 54% of revenue with strong growth in CDMO and B2B segments - Europe revenue up 20% y-y; Other core markets declined due to volume drop - Rest of World revenue grew 2% y-y; India CDMO up 12%, B2B declined 36%